查詢結果分析
相關文獻
頁籤選單縮合
題 名 | Cognitive MRI-TRUS Fusion-Targeted Prostate Biopsy According to PI-RADS Classification in Patients with Prior Negative Systematic Biopsy Results |
---|---|
作 者 | Lai, Wei-jen; Wang, Hsin-kai; Liu, Hsian-tzu; Park, Byung Kwan; Shen, Shu-huei; Lin, Tzu-ping; Chung, Hsiao-jen; Huang, Yi-hsiu; Chang, Yen-hwa; | 書刊名 | Journal of the Chinese Medical Association |
卷 期 | 79:11 2016.11[民105.11] |
頁 次 | 頁618-624 |
分類號 | 416.275 |
關鍵詞 | Image-guided biopsy; Magnetic resonance imaging; Prostate; Prostate cancer; Prostate-specific antigen; |
語 文 | 英文(English) |
英文摘要 | Background The purpose of this study was to evaluate the prostate cancer yield rate of targeted transrectal ultrasound (TRUS)-guided biopsy with cognitive magnetic resonance imaging (MRI) registration without concurrent systematic biopsy in patients with previous negative systematic TRUS-guided biopsy results and persistently elevated prostate-specific antigen (PSA) levels. Methods In this prospective study conducted from August 2013 to January 2015, patients with at least one previous negative systematic TRUS-guided biopsy and persistently high PSA (≥4 ng/mL) levels were referred for multiparametric MRI (mpMRI). Those patients with suspicious findings on mpMRI received a subsequent cognitive MRI-TRUS fusion biopsy. The cancer-detection rate, tumor location, and Gleason score were confirmed, and PSA-related data were compared between cancer-yield and noncancer-yield groups. Results In total, 48 patients were included in this study. MRI was designated to be four and five in 17 patients. Fifteen patients received a cognitive fusion-targeted biopsy, and prostate cancers were detected in 10 patients. The cancer-detection rate was 20.8% (10/48), and the positive-predictive value of MRI was 66.7%. No significant differences were observed in the PSA level, PSA velocity, or transitional zone volume between the cancer-yield and noncancer-yield groups; however, the corresponding difference in PSA transitional zone density was significant ( p = 0.025). Conclusion Cognitive MRI-TRUS fusion-targeted biopsy without concurrent systematic biopsy can detect significant prostate cancer in patients with previous negative systematic biopsy results and persistently elevated PSA levels. Noncancer-yield patients should undergo active surveillance and further follow-ups. |
本系統中英文摘要資訊取自各篇刊載內容。